|
Cascales Campos PA, Gonzalez Gil A. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer. Ann Surg Oncol. 2022 May;29(5):3361-3362. doi: 10.1245/s10434-022-11501-8. Epub 2022 Mar 7. No abstract available. PubMed PMID: 35254577.
AÑO: 2022; IF: 3.7
|
35254577
|
Antonio CCP, Alida GG, Elena GG, Rocio GS, Jeronimo MG, Luis ARJ, Anibal ND, Francisco BV, Jesus GRA, Pablo RR, Jose GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PubMed PMID: 34812982.
AÑO: 2022; IF: 3.7
|
|
Cascales Campos PA, Gonzalez Gil A, Gomez Ruiz AJ, Balaguer Roman A, Gil Gomez E, Alconchel Gago F, Martinez J, Nieto Diaz A, Barcelo Valcarcel F, Gil Martinez J. Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections. Clin Transl Oncol. 2022 Aug;24(8):1542-1548. doi: 10.1007/s12094-022-02795-x. Epub 2022 Mar 10. PubMed PMID: 35274202.
AÑO: 2022; IF: 3.4
|
|
Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2021 Jan;47(1):4-10. doi: 10.1016/j.ejso.2019.03.012. Epub 2019 Mar 23. PubMed PMID: 30954350.
AÑO: 2021; IF: 4.037
|
|
Cascales-Campos PA, Gonzalez-Gil A, Fernandez-Luna E, Gil-Gomez E, Alconchel-Gago F, Romera-Garcia A, Martinez-Garcia J, Nieto-Diaz A, Barcelo-Valcarcel F, Gil-Martinez J. Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS + HIPEC. Surg Oncol. 2021 Mar;36:115-119. doi: 10.1016/j.suronc.2020.12.001. Epub 2020 Dec 11. PubMed PMID: 33341606.
AÑO: 2021; IF: 2.388
|